Berberine 관련 Gut Dysbiosis
DPreclinical evidence that berberine modulates microbiome composition. Limited human microbiome data.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dberberine\u0026condition\u003Dgut\u002Ddysbiosis';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
D
결론
Preclinical evidence that berberine modulates microbiome composition. Limited human microbiome data.
Key Study Findings
Other
Design and Activity Evaluation of Berberine-Loaded Dual pH and Enzyme-Sensitive Colon-Targeting Microparticles.
Dose: None
vs: Free berberine; DSS-induced UC model vs normal mice
Outcome: DAI scores, inflammatory cytokines, gut microbiota
효과: None
<0.01 (DAI); <0.05 (cytokines)
대상 집단: DSS-induced UC mouse model (male KM mice)
Review
Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver …
Dose: None
vs: None
Outcome: None
효과: None
None
대상 집단: None
Other
Oxyberberine alleviates fructose-induced hyperuricemia by modulating purine metabolism and gut microbiota.
Dose: None
vs: Fructose-induced HUA control
Outcome: Serum uric acid levels
효과: None
None
대상 집단: Fructose-induced hyperuricemia rats
Review
Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent.
Dose: None
vs: None
Outcome: None
효과: None
None
대상 집단: None
Other
Co-administration of berberine and evodiamine: Mitigating evodiamine-induced hepatotoxicity and potentiating colitis treatment.
Dose: None
vs: EVO alone; colitis mouse model
Outcome: Hepatotoxicity markers and colitis inflammation
효과: None
None
대상 집단: C57 mice (normal and colitis models)
In Vitro
1 weeks
Phellodendron bark extract and berberine chloride suppress microbiome dysbiosis in a saliva-derived in vitro microcosm …
Dose: None
vs: Untreated biofilm control
Outcome: Microbiome dysbiosis suppression in biofilm
효과: None
None
대상 집단: Saliva-derived in vitro microcosm biofilm model with P. gingivalis
Key Statistics
2
연구
100
참여자
↑
Positive
D
등급
Referenced Papers
International journal of …
2025
15 인용
Colloids and surfaces. …
2025
11 인용
Pharmaceuticals (Basel, Switzerland)
2025
8 인용
Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent.
Review
Pharmaceuticals (Basel, Switzerland)
2025
8 인용
Inflammatory bowel diseases
2025
2 인용
Pharmaceutics
2025
2 인용
Phytomedicine : international …
2025
2 인용
The Journal of …
2025
1 인용
European journal of …
2025
Archives of oral …
2025
Frontiers in nutrition
2025
Biomedicine & pharmacotherapy …
2024
17 인용
Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature.
Systematic Review
International journal of …
2024
14 인용
Frontiers in pharmacology
2024
9 인용
Hepatology communications
2024
9 인용
Frontiers in microbiology
2024
6 인용
Frontiers in microbiology
2024
5 인용
Indian journal of …
2024
2 인용
Gut microbes
2023
108 인용
Biomedicine & pharmacotherapy …
2023
61 인용
International journal of …
2023
48 인용
Journal of ethnopharmacology
2023
29 인용
Frontiers in pharmacology
2023
20 인용
International journal of …
2023
18 인용
Current pharmaceutical design
2023
10 인용
Journal of oral …
2023
10 인용
Journal of neurogastroenterology …
2023
4 인용
Berberine interacts with gut microbiota and its potential therapy for polycystic ovary syndrome.
Review
Clinical and experimental …
2023
2 인용
Microorganisms
2022
212 인용
Food & function
2022
83 인용
Phytomedicine : international …
2022
67 인용
Biomaterials science
2022
34 인용
Microbiology spectrum
2022
25 인용
Brazilian journal of …
2022
12 인용
Pharmacological research
2021
186 인용
Pharmacological research
2021
147 인용
Acta pharmacologica Sinica
2021
63 인용
Frontiers in pharmacology
2021
42 인용
Frontiers in immunology
2021
22 인용
Comprehensive Physiology
2021
21 인용
International journal of …
2021
20 인용
Targeting gut barrier dysfunction with phytotherapies: Effective strategy against chronic diseases.
Review
Pharmacological research
2020
65 인용
Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review.
Systematic Review
Journal of integrative …
2020
33 인용
Pharmacological research
2019
166 인용
American journal of …
2019
117 인용
Biomedicine & pharmacotherapy …
2019
72 인용
Scientific reports
2019
51 인용
Pharmacological research
2019
31 인용
Science China. Life …
2018
17 인용
Alternative therapies in …
2017
9 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 500-1,500 mg/day in divided doses
- siboprotocol:
- 500 mg two to three times daily for 4 weeks (as part of herbal antimicrobial protocol)
- giantimicrobial:
- 500 mg twice daily
상한량: Generally well-tolerated up to 1,500 mg/day in divided doses
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | 1 weeks | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
권장 복용 시간: With meals; divide doses throughout the day (do not take full daily dose at once)
Safety & Side Effects
보고된 부작용
- ⚠ GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common
- ⚠ May cause uterine contractions (contraindicated in pregnancy)
- ⚠ Headache
- ⚠ Skin rash (rare)
알려진 상호작용
- ● Diabetes medications (berberine significantly lowers blood sugar; risk of hypoglycemia)
- ● Cyclosporine (berberine inhibits CYP3A4, increasing cyclosporine levels)
- ● Anticoagulants (may have additive blood-thinning effects)
- ● Metformin (additive glucose-lowering effect; monitor closely)
- ● Macrolide antibiotics (berberine inhibits CYP3A4)
일일 최대 섭취 허용량: Generally well-tolerated up to 1,500 mg/day in divided doses
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does Berberine help with Gut Dysbiosis?
Based on 2 studies with 100 participants, there is preliminary evidence that needs more research that Berberine may support Gut Dysbiosis management. Our evidence grade is D (Very Early Research).
How much Berberine should I take for Gut Dysbiosis?
Studies have used various dosages. A commonly studied range is 500-1,500 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Berberine?
Reported side effects may include GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common, May cause uterine contractions (contraindicated in pregnancy), Headache, Skin rash (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Berberine and Gut Dysbiosis?
We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 100 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: Gut Dysbiosis
Berberine 다른 건강 상태에 대한 근거
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.